Ketogenic diet safe and effective for managing drug-resistant epilepsy among kids
Egypt: A ketogenic diet appears to be a safe and effective non-pharmacologic, non-surgical therapy for managing childhood drug-resistant epilepsy (DRE) with a positive impact on EEG and growth and no significant side effects, a recent study has shown. The study was published in Pediatric Research on 11 March 2023.
Drug-resistant epilepsy, as defined by the ILAE (The International League Against Epilepsy), is the failure of adequate trials of two tolerated, properly selected and utilized antiepileptic drug schedules to obtain sustained seizure relief.
A ketogenic diet (KD) is a low-carbohydrate, adequate protein, and high-fat diet which is touted to be a non-invasive, effective, and non-pharmacologic treatment for refractory childhood epilepsy with no neurotoxic effects as compared to multiple anti-seizure medications (ASM). KD is suggested to operate through ketosis (which mimics a starving state), higher fatty acid levels, decreased glucose, neuroprotective properties, and anti-epileptogenic properties. Ketones may also confer neurologic protection, and ketone bodies could confer anti-inflammatory, anti-oxidative, epigenetic, cellular, and gut-microbiome alterations.
Most patients, however, have diet discontinuation because of its restrictive and unpalatable features. So, new KD variants have emerged, including the low-glycemic-index diet and modified Atkins diet (MAD). MAD provides a less restrictive and more palatable dietary treatment option. There is still an ongoing debate on the effectiveness of MAD compared to classic KD.
Against the above background, Ali M. El-Shafie, Menoufia University, Shebin El-Kom, Egypt, and colleagues aimed to assess short- and long-term efficacy, tolerability, and safety of ketogenic diet (classic KD and MAD) in childhood DRE. They also investigated the effect of KD on EEG (electroencephalography) features of children with DRE.
The study included forty patients with DRE diagnosis per the ILAE. They were randomly assigned into classic KD or MAD groups. Investigation of KD was done after lipid, clinical profile and EEG documentation. They were regularly followed for 24 months. Thirty completed this study of 40 patients with DRE.
Six patients could not tolerate KD and were removed from the study (85% tolerability), three more patients were excluded due to parental noncompliance, and one died during the study period. Overall reasons for dropout mainly were GI tract adverse events.
Overall reasons for dropout mainly were diet intolerance, AEs (primarily GI tract related), weight loss, parental unhappiness and change of mind.
The study revealed the following findings:
- Both MAD and classic KD were effective in seizure control as 60% in the classic KD group and 53.33% in the MAD group became seizure-free, and the remaining showed ≥50% seizure reduction.
- The lipid profile remained within acceptable levels in both groups throughout the study period.
- Adverse effects were managed medically and mild with improved growth parameters and EEG during the study period.
A ketogenic diet (classic KD and MAD) appears to be an effective and well-tolerated therapy in treating children with DRE with a positive impact on growth and EEG and no significant side effects.
"KD's role as a single line of therapy, whether from the beginning or following the withdrawal of all other medications once the establishment of full control, is also recommended to be clarified by more studies," the researchers concluded.
Reference:
El-Shafie, A.M., Bahbah, W.A., Abd El Naby, S.A. et al. Impact of two ketogenic diet types in refractory childhood epilepsy. Pediatr Res (2023). https://doi.org/10.1038/s41390-023-02554-w
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.